EOG
30
-2
JPM
64
2
WHR
59
-2
BIIB
42
2
NEE
42
-2
ROST
66
4
NTRS
47
3
SE
58
-2
M
55
7
AES
49
-2
ICE
57
2
MMM
40
3
ORLY
48
-4
PEP
33
-3
VIX
15
7
CHD
39
2
CNP
52
-2
EMN
42
2
ROP
50
2
PLD
45
5
EOG
30
-2
JPM
64
2
WHR
59
-2
BIIB
42
2
NEE
42
-2
ROST
66
4
NTRS
47
3
SE
58
-2
M
55
7
AES
49
-2
ICE
57
2
MMM
40
3
ORLY
48
-4
PEP
33
-3
VIX
15
7
CHD
39
2
CNP
52
-2
EMN
42
2
ROP
50
2
PLD
45
5
Financhill
Back

Aligos Therapeutics 10K Form

Buy
65

ALGS
Aligos Therapeutics

Last Price:
$43.62
Seasonality Move:
7.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALGS News And Ratings

See the #1 stock for the next 7 days that we like better than ALGS

ALGS Financial Statistics

Sales & Book Value

Annual Sales: $15.5M
Cash Flow: $-20.1M
Price / Cash Flow: 0
Annual Sales: $15.07
Price / Book: 3.11

Profitability

EPS (TTM): -17.10530
Net Income (TTM): $-77M
Gross Margin: --
Return on Equity: -118.75%
Return on Assets: -68.4%

Aligos Therapeutics Earnings Forecast

Key Aligos Therapeutics Financial Ratios

  • The Research & Development expenses have been 470.35% of Revenue.
  • The Net Earning history of ALGS is -564.61% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 3 years.

Aligos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALGS
Website: aligos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.81
Quick Ratio: 3.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALGS Technical Analysis vs Fundamental Analysis

Buy
65
Aligos Therapeutics (ALGS) is a Buy

Is Aligos Therapeutics a Buy or a Sell?